Larimar Therapeutics (LRMR) Debt to Equity (2016 - 2020)
Historic Debt to Equity for Larimar Therapeutics (LRMR) over the last 7 years, with Q1 2020 value amounting to $0.13.
- Larimar Therapeutics' Debt to Equity fell 1903.24% to $0.13 in Q1 2020 from the same period last year, while for Mar 2020 it was $0.13, marking a year-over-year decrease of 1903.24%. This contributed to the annual value of -$12.2 for FY2019, which is 759114.19% down from last year.
- Per Larimar Therapeutics' latest filing, its Debt to Equity stood at $0.13 for Q1 2020, which was down 1903.24% from -$12.2 recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' Debt to Equity ranged from a high of $0.36 in Q2 2018 and a low of -$12.2 during Q4 2019
- Over the past 5 years, Larimar Therapeutics' median Debt to Equity value was $0.16 (recorded in 2018), while the average stood at -$0.79.
- Over the last 5 years, Larimar Therapeutics' Debt to Equity had its largest YoY gain of 475.95% in 2019, and its largest YoY loss of 759114.19% in 2019.
- Larimar Therapeutics' Debt to Equity (Quarter) stood at $0.01 in 2016, then soared by 2673.76% to $0.26 in 2017, then plummeted by 36.33% to $0.16 in 2018, then crashed by 7591.14% to -$12.2 in 2019, then soared by 101.09% to $0.13 in 2020.
- Its Debt to Equity stands at $0.13 for Q1 2020, versus -$12.2 for Q4 2019 and $0.17 for Q3 2019.